Trade Aldeyra Therapeutics, Inc. - ALDX CFD
Add to favourite- Summary
- Historical Data
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 3.92 |
Open | 3.84 |
1-Year Change | -59.19% |
Day's Range | 3.84 - 4.01 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 25, 2024 | 3.91 | 0.05 | 1.30% | 3.86 | 4.02 | 3.82 |
Apr 24, 2024 | 3.92 | 0.03 | 0.77% | 3.89 | 3.97 | 3.86 |
Apr 23, 2024 | 3.88 | -0.01 | -0.26% | 3.89 | 4.16 | 3.88 |
Apr 22, 2024 | 3.90 | 0.06 | 1.56% | 3.84 | 4.01 | 3.78 |
Apr 19, 2024 | 3.84 | -0.10 | -2.54% | 3.94 | 3.97 | 3.76 |
Apr 18, 2024 | 3.96 | 0.06 | 1.54% | 3.90 | 4.05 | 3.87 |
Apr 17, 2024 | 3.95 | 0.11 | 2.86% | 3.84 | 4.12 | 3.79 |
Apr 16, 2024 | 3.85 | -0.19 | -4.70% | 4.04 | 4.06 | 3.82 |
Apr 15, 2024 | 4.14 | -0.02 | -0.48% | 4.16 | 4.29 | 4.03 |
Apr 12, 2024 | 4.23 | -0.12 | -2.76% | 4.35 | 4.44 | 4.17 |
Apr 11, 2024 | 4.37 | 0.16 | 3.80% | 4.21 | 4.45 | 4.18 |
Apr 10, 2024 | 4.22 | -0.02 | -0.47% | 4.24 | 4.26 | 4.07 |
Apr 9, 2024 | 4.40 | -0.14 | -3.08% | 4.54 | 4.65 | 4.31 |
Apr 8, 2024 | 4.35 | -0.54 | -11.04% | 4.89 | 4.89 | 4.27 |
Apr 5, 2024 | 4.69 | 0.05 | 1.08% | 4.64 | 4.90 | 4.56 |
Apr 4, 2024 | 4.66 | 0.14 | 3.10% | 4.52 | 4.85 | 4.37 |
Apr 3, 2024 | 4.13 | 0.51 | 14.09% | 3.62 | 4.19 | 3.60 |
Apr 2, 2024 | 3.53 | 0.31 | 9.63% | 3.22 | 3.54 | 3.17 |
Apr 1, 2024 | 3.25 | -0.03 | -0.91% | 3.28 | 3.31 | 3.10 |
Mar 28, 2024 | 3.24 | 0.13 | 4.18% | 3.11 | 3.48 | 3.11 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Aldeyra Therapeutics, Inc. Company profile
About Aldeyra Therapeutics Inc
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in developing immune-modulating therapies to treat ocular and systemic diseases. The Company's lead product candidate, reproxalap, is a treatment in late-stage development for dry eye disease (DED) and allergic conjunctivitis (AC). It has additional product candidates in development for proliferative vitreoretinopathy (PVR), primary vitreoretinal lymphoma (PVRL) and other retinal diseases, autoimmune disease, and cancer. The Company's product development pipeline is focused on immune-mediated ocular diseases and select systemic diseases and encompasses three biological mechanisms of action: reactive aldehyde species (RASP) inhibition, dihydrofolate reductase (DHFR) inhibition, and protein chaperome (CHP) inhibition. The immunological activity of its product candidates generally leads to diminished levels of pathological inflammation via down-regulation of immune cell activation or proliferation.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Aldeyra Therapeutics Inc revenues was not reported. Net loss increased 54% to $57.8M. Higher net loss reflects Research and development increase of 98% to $41.4M (expense), General and administrative increase of 15% to $7.7M (expense), General and administrative expenses increase of 8% to $3.5M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.11 to -$1.07.
Industry: | Bio Therapeutic Drugs |
131 Hartwell Avenue
Suite 320
LEXINGTON
MASSACHUSETTS 02421
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com